|
1）Yaoita H, Takase S, Maruyama Y, et al. Scintigraphic assessment of the effects of bone marrow-derived mononuclear cell transplantation combined with off-pump coronary artery bypass surgery in patients with ischemic heart disease. J Nucl Med. 2005; 46: 1610-7
|
|
|
|
2）Yacoub MH, Terrovitis J. CADUCEUS, SCIPIO, ALCADIA: Cell therapy trials using cardiac-derived cells for patients with post myocardial infarction LV dysfunction, still evolving. Glob Cardiol Sci Pract. 2013; 2013: 5-8
|
|
|
|
|
|
3）Sawa Y, Yoshikawa Y, Toda K, et al. Safety and efficacy of autologous skeletal myoblast sheets (TCD-51073) for the treatment of severe chronic heart failure due to ischemic heart disease. Circ J. 2015; 79: 991-9
|
|
|
|
|
4）Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131: 861-72
|
|
|
|
|
|
5）Go AS, Mozaffarian D, Roger VL, et al. Heart Disease and Stroke Statistics-2013 Update A Report From the American Heart Association. Circulation. 2013; 127: e6-e245
|
|
|
|
|
|
6）Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009; 361: 2241-51
|
|
|
|
|
|
7）Laflamme MA, Murry CE. Heart regeneration. Nature. 2011; 473: 326-35
|
|
|
|
|
|
8）van Berlo JH, Molkentin JD. An emerging consensus on cardiac regeneration. Nat Med. 2014; 20: 1386-93
|
|
|
|
|
|
9）Masumoto H, Sakata R. Cardiovascular surgery for realization of regenerative medicine. Gen Thorac Cardiovasc Surg. 2012; 60: 744-55
|
|
|
|
|
|
10）Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001; 410: 701-5
|
|
|
|
|
|
11）Sakakibara Y, Tambara K, Lu FL, et al. Combined procedure of surgical repair and cell transplantation for left ventricular aneurysm: An experimental study. Circulation. 2002; 106: I193-7
|
|
|
|
|
|
12）Menasche P, Alfieri O, Janssens S, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation. 2008; 117: 1189-200
|
|
|
|
|
|
13）Gerbin KA, Murry CE. The winding road to regenerating the human heart. Cardiovasc Pathol. 2015; 24: 133-40
|
|
|
|
|
|
14）Simari RD, Pepine CJ, Traverse JH, et al. Bone marrow mononuclear cell therapy for acute myocardial infarction: a perspective from the cardiovascular cell therapy research network. Circ Res. 2014; 114: 1564-8
|
|
|
|
|
|
15）Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004; 364: 141-8
|
|
|
|
|
|
16）Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J. 2009; 30: 2978-84
|
|
|
|
|
|
17）Schachinger V, Erbs S, Elsasser A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006; 355: 1210-21
|
|
|
|
|
|
18）Assmus B. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002; 106: 3009-17
|
|
|
|
|
|
19）Leistner DM, Fischer-Rasokat U, Honold J, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy. Clin Res Cardiol. 2011; 100: 925-34
|
|
|
|
|
|
20）Simari RD, Moye LA, Skarlatos SI, et al. Development of a network to test strategies in cardiovascular cell delivery: the NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTRN). J Cardiovasc Transl Res. 2010; 3: 30-6
|
|
|
|
|
|
21）Perin EC, Willerson JT, Pepine CJ, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 2012; 307: 1717-26
|
|
|
|
|
|
22）Traverse JH, Henry TD, Ellis SG, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011; 306: 2110-9
|
|
|
|
|
|
23）Traverse JH, Henry TD, Pepine CJ, et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012; 308: 2380-9
|
|
|
|
|
|
24）Heldman AW, DiFede DL, Fishman JE, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014; 311: 62-73
|
|
|
|
|
|
25）Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012; 308: 2369-79
|
|
|
|
|
|
26）Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013; 61: 2329-38
|
|
|
|
|
|
27）Li TS, Cheng K, Malliaras K, et al. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J Am Coll Cardiol. 2012; 59: 942-53
|
|
|
|
|
|
28）Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003; 114: 763-76
|
|
|
|
|
|
29）Bolli R, Chugh AR, D’Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011; 378: 1847-57
|
|
|
|
|
|
30）The Lancet Editors. Expression of concern: the SCIPIO trial. Lancet. 2014; 383: 1279
|
|
|
|
|
|
31）Malliaras K, Makkar RR, Smith RR, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol. 2014; 63 110-22
|
|
|
|
|
|
32）Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012; 379: 895-904
|
|
|
|
|
|
33）Takehara N, Tsutsumi Y, Tateishi K, et al. Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction. J Am Coll Cardiol. 2008; 52: 1858-65
|
|
|
|
|
|
34）Menasche P. Stem cell therapy for chronic heart failure: lessons from a 15-year experience. C R Biol. 2011; 334: 489-96
|
|
|
|
|
|
35）van Berlo JH, Kanisicak O, Maillet M, et al. c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature. 2014; 509: 337-41
|
|
|
|
|
|
36）Thomson JA. Embryonic Stem Cell Lines Derived from Human Blastocysts. Science. 1998; 282: 1145-7
|
|
|
|
|
|
37）Yamashita J, Itoh H, Hirashima M, et al. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature. 2000; 408: 92-6
|
|
|
|
|
|
38）Yamashita JK, Takano M, Hiraoka-Kanie M, et al. Prospective identification of cardiac progenitors by a novel single cell-based cardiomyocyte induction. Faseb J. 2005; 19: 1534
|
|
|
|
|
|
39）Narazaki G, Uosaki H, Teranishi M, et al. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation. 2008; 118: 498-506
|
|
|
|
|
|
40）Uosaki H, Fukushima H, Takeuchi A, et al. Efficient and Scalable Purification of Cardiomyocytes from Human Embryonic and Induced Pluripotent Stem Cells by VCAM1 Surface Expression. Plos One. 2011; 6: e23657
|
|
|
|
|
|
41）Masumoto H, Ikuno T, Takeda M, et al. Human iPS cell-engineered cardiac tissue sheets with cardiomyocytes and vascular cells for cardiac regeneration. Sci Rep. 2014; 4: 6716
|
|
|
|
|
|
42）Okano T, Yamada N, Sakai H, et al. A Novel Recovery-System for Cultured-Cells Using Plasma-Treated Polystyrene Dishes Grafted with Poly(N-Isopropylacrylamide). J Biomedi Materials Res. 1993; 27: 1243-51
|
|
|
|
|
|
43）Masumoto H, Matsuo T, Yamamizu K, et al. Pluripotent stem cell-engineered cell sheets reassembled with defined cardiovascular populations ameliorate reduction in infarct heart function through cardiomyocyte-mediated neovascularization. Stem Cells. 2012; 30: 1196-205
|
|
|
|
|
|
44）Menasche P, Vanneaux V, Hagege A, et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur Heart J. 2015; 36: 2011-7
|
|
|
|
|
|
45）Ieda M, Fu JD, Delgado-Olguin P, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell. 2010; 142: 375-86
|
|
|
|
|
|
46）Qian L, Huang Y, Spencer CI, et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature. 2012; 485: 593-8
|
|
|
|
|
|
47）Butler D. Translational research: crossing the valley of death. Nature. 2008; 453: 840-2
|
|
|
|
|